Urovant Sciences (UROV) Stock Price, News & Analysis

Company Overview

Urovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for urologic conditions in the United States. The company's lead product candidate is vibegron, an oral small molecule beta-3 agonist for the treatment of overactive bladder (OAB), OAB in men with benign prostatic hyperplasia, and abdominal pain due to irritable bowel syndrome. It is also developing URO-902, a gene therapy for patients with OAB who have failed oral pharmacological therapy. The company was formerly known as Thalavant Sciences Ltd. and changed its name to Urovant Sciences Ltd. in January 2017. Urovant Sciences Ltd. was founded in 2016 and is based in London, the United Kingdom. Urovant Sciences Ltd. operates as a subsidiary of Sumitovant Biopharma Ltd.

Key Stats

• Today's Range: $16.24 to $16.24
• 50-Day Range: $16.19 to $16.24
• 52-Week Range: $7.15 to $16.26
• Volume: N/A
• Average Volume: 114,469 shs
• Market Capitalization: $531.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

UROV Stock Analysis - Frequently Asked Questions

How were Urovant Sciences' earnings last quarter?

Urovant Sciences Ltd. (NASDAQ:UROV) announced its quarterly earnings results on Thursday, February, 11th. The company reported ($1.46) EPS for the quarter, topping analysts' consensus estimates of ($1.59) by $0.13.

When did Urovant Sciences IPO?

Urovant Sciences (UROV) raised $150 million in an initial public offering (IPO) on Thursday, September 27th 2018. The company issued 10,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Jefferies and Cowen served as the underwriters for the IPO.

What other stocks do shareholders of Urovant Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Urovant Sciences investors own include Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Xeris Biopharma (XERS), Akero Therapeutics (AKRO), Aldeyra Therapeutics (ALDX), Idera Pharmaceuticals (IDRA) and Kaleido Biosciences (KLDO).

Company Calendar

• Last Earnings: 2/11/2021
• Today: 10/17/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:UROV
• CUSIP: N/A
• CIK: 1740547
• Web: www.urovant.com
• Phone: 44-0-20-7400-3347
• Fax: N/A
• Employees: 70
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($4.71)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-146,740,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: -162.90%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.91
• Quick Ratio: 2.91

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.90) per share
• Price / Book: -8.55

Miscellaneous

• Outstanding Shares: 32,743,000
• Free Float: N/A
• Market Cap: $531.75 million
• Optionable: Not Optionable
• Beta: 2.36